Filament Health Corp. announced interim safety reporting from its Phase I clinical trial in partnership with the University of California, San Francisco (UCSF)'s Translational Psychedelic Research Program (TrPR). Four healthy subjects have been dosed with Filament's botanical psilocybin drug candidate, PEX010, as well as the Company's botanical psilocin drug candidates, PEX020 and PEX030.

Fifteen doses of Filament's drug candidates have been given, and all were reported to be well tolerated with no serious or unexpected adverse events. This is the first FDA-approved clinical trial of a naturally-derived psychedelic drug candidate, as well as the first time that psilocin has been directly administered in a clinical trial.